Indications for: UPTRAVI FOR INJECTION
Pulmonary arterial hypertension (PAH) (WHO Group 1) in patients with WHO functional Class II–III symptoms, to delay disease progression and reduce the risk of hospitalization for PAH, when oral therapy is not feasible.
Give by IV infusion over 80mins twice daily. For corresponding IV dose based on current dose of Uptravi tabs: see full labeling. Moderate hepatic impairment (Child-Pugh class B), concomitant moderate CYP2C8 inhibitors: reduce Uptravi dose to once daily.
UPTRAVI FOR INJECTION Contraindications:
Concomitant strong CYP2C8 inhibitors (eg, gemfibrozil).
UPTRAVI FOR INJECTION Warnings/Precautions:
Discontinue if pulmonary veno-occlusive disease confirmed. Severe hepatic impairment (Child-Pugh class C): avoid. Pregnancy. Nursing mothers: not recommended.
UPTRAVI FOR INJECTION Classification:
Prostacyclin receptor agonist.
UPTRAVI FOR INJECTION Interactions:
See Contraindications. Potentiated by moderate CYP2C8 inhibitors (eg, clopidogrel, deferasirox, teriflunomide); reduce dosing (see Adults). Antagonized by CYP2C8 and UGT 1A3 or 2B7 inducers (eg, rifampin); increase up to twice the dose.
Headache, diarrhea, nausea, jaw pain, vomiting, pain in extremity, myalgia, flushing, arthralgia, rash, anemia, decreased appetite.
Generic Drug Availability:
Tabs 200mcg—60, 140; 400mcg, 600mcg, 800mcg, 1000mcg, 1200mcg, 1400mcg, 1600mcg—60; Titration pack—1 (140 x 200mcg tabs) + (60 x 800mcg tabs); Single-dose vial (10mL)—1